🇺🇸 Intravenous immunoglobulin in United States

234 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Drug Ineffective — 68 reports (29.06%)
  2. Drug Ineffective For Unapproved Indication — 61 reports (26.07%)
  3. Off Label Use — 21 reports (8.97%)
  4. Headache — 15 reports (6.41%)
  5. Nerve Degeneration — 14 reports (5.98%)
  6. Dyspnoea — 13 reports (5.56%)
  7. Condition Aggravated — 12 reports (5.13%)
  8. Neurological Symptom — 12 reports (5.13%)
  9. Diarrhoea — 9 reports (3.85%)
  10. Hypertension — 9 reports (3.85%)

Source database →

Intravenous immunoglobulin in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Intravenous immunoglobulin approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Intravenous immunoglobulin in United States?

University of Calgary is the originator. The local marketing authorisation holder may differ — check the official source linked above.